Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tim J. A. Hutten"'
Autor:
Maaike A. Sikma, Imo E. Hoefer, Marjon Wesseling, Wouter M. Tiel Groenestege, Ron H. Stokwielder, Tim J A Hutten
Publikováno v:
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 36(4)
Autor:
Tim J. A. Hutten, J.H. Frederik Falkenburg, Willemijn Hobo, Michel G.D. Kester, Nicolaas Schaap, Rob Woestenenk, Sofia Berglund, Leo Luznik, Joop H. Jansen, Frans Maas, Wieger J. Norde, Ruo Chen Wang, Harry Dolstra
Publikováno v:
Biology of Blood and Marrow Transplantation, 24, 666-677
Biology of Blood and Marrow Transplantation, 24(4), 666-677
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, 24, 4, pp. 666-677
Biology of Blood and Marrow Transplantation, 24(4), 666-677
Biology of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation, 24, 4, pp. 666-677
Allogeneic stem cell transplantation (allo-SCT) can be a curative treatment for patients with a hematologic malignancy due to alloreactive T cell responses recognizing minor histocompatibility antigens (MiHA). Yet tumor immune escape mechanisms can c
Autor:
Joop H. Jansen, Rob Woestenenk, Lex B. H. Bakker, Tim J. A. Hutten, Willemijn Hobo, Ben Joosten, Nicolaas Schaap, Hanny Fredrix, Harry Dolstra, Alessandra Cambi, Jurjen Tel, Soley Thordardottir, Gerben M. Franssen, Lisanne M. A. Janssen, Otto C. Boerman, Mirjam H.M. Heemskerk
Publikováno v:
Journal of Immunology, 197, 7, pp. 2715-25
Journal of Immunology, 197, 2715-25
Journal of Immunology, 197(7), 2715-2725
Journal of Immunology, 197, 2715-25
Journal of Immunology, 197(7), 2715-2725
Contains fulltext : 172057.pdf (Publisher’s version ) (Closed access) Potent immunotherapies are urgently needed to boost antitumor immunity and control disease in cancer patients. As dendritic cells (DCs) are the most powerful APCs, they are an at
Publikováno v:
British Journal of Haematology, 181, 38-53
British Journal of Haematology, 181, 1, pp. 38-53
British Journal of Haematology, 181, 1, pp. 38-53
Contains fulltext : 190712.pdf (Publisher’s version ) (Closed access) New immunotherapeutic interventions have revolutionized cancer treatment. The immune responsiveness of acute myeloid leukaemia (AML) was first demonstrated by allogeneic stem cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6328fa2fa193855f4df9d556b222074
https://doi.org/10.1111/bjh.15078
https://doi.org/10.1111/bjh.15078
Autor:
Tim J A, Hutten, Wieger J, Norde, Rob, Woestenenk, Ruo Chen, Wang, Frans, Maas, Michel, Kester, J H Frederik, Falkenburg, Sofia, Berglund, Leo, Luznik, Joop H, Jansen, Nicolaas, Schaap, Harry, Dolstra, Willemijn, Hobo
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 24(4)
Allogeneic stem cell transplantation (allo-SCT) can be a curative treatment for patients with a hematologic malignancy due to alloreactive T cell responses recognizing minor histocompatibility antigens (MiHA). Yet tumor immune escape mechanisms can c
Autor:
Viggo Van Tendeloo, Willemijn Hobo, Hans De Reu, Johan M.J. Van den Bergh, Evelien Smits, Eva Lion, Tim J. A. Hutten, Zwi N. Berneman, Harry Dolstra
Publikováno v:
Cancer immunology research
Cancer Immunology Research, 5, 8, pp. 710-715
Cancer Immunology Research, 5, 710-715
Cancer Immunology Research, 5, 8, pp. 710-715
Cancer Immunology Research, 5, 710-715
Contains fulltext : 177224.pdf (Publisher’s version ) (Closed access) Although allogeneic stem cell transplantation (allo-SCT) can elicit graft-versus-tumor (GVT) immunity, patients often relapse due to residual tumor cells. As essential orchestrat
Autor:
Soley Thordardottir, Jan Spanholtz, Harry Dolstra, Tim J. A. Hutten, Marta Cossu, Robbert van der Voort, Basav N. Hangalapura, Nicolaas Schaap, Timothy R D J Radstake
Publikováno v:
Stem Cells and Development, 23, 9, pp. 955-67
Stem Cells and Development, 23, 955-67
Stem Cells and Development, 23, 955-67
Contains fulltext : 136942.pdf (Publisher’s version ) (Closed access) The superiority of dendritic cells (DCs) as antigen-presenting cells has been exploited in numerous clinical trials, where generally monocyte-derived DCs (Mo-DCs) are injected to
Autor:
Willemijn Hobo, Harry Dolstra, Tim J. A. Hutten, Basav N. Hangalapura, Anniek B. van der Waart, Jeannette Cany, Soley Thordardottir, Jessica Hübel
Publikováno v:
Journal of Immunotherapy (1997), 37, 5, pp. 267-277
ResearcherID
Journal of Immunotherapy (1997), 37, 267-277
ResearcherID
Journal of Immunotherapy (1997), 37, 267-277
Autologous, patient-specific, monocyte-derived dendritic cell (MoDC) vaccines have been successfully applied in the clinical studies so far. However, the routine application of this strategy has been hampered by the difficulties in generating suffici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c99fbc2dcabc4bc654d8ab54cc1bd513
https://hdl.handle.net/2066/137981
https://hdl.handle.net/2066/137981
Autor:
Marta Cossu, Robbert van der Voort, Jan Spanholtz, Soley Thordardottir, Tim J. A. Hutten, Hangalapura Basav N., Timothy R D J Radstake, Nicolaas Schaap, Harry Dolstra
Publikováno v:
ResearcherID
The prominent role of dendritic cells (DCs) in T cell activation is the rational for DC-based immunotherapy of cancer and infectious diseases. In cancer, DC therapy aims to induce tumor-specific effector T cell responses that can reduce or eliminate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c44ea372b2d42d3a5933bc67a2e69324
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000331385004212&KeyUID=WOS:000331385004212
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000331385004212&KeyUID=WOS:000331385004212